This evidence highlights Tax as a promising therapeutic target, as the absence of Tax renders primary ATLL cells unable to survive, despite the presence of somatic mutations and HBZ (Hleihel et al., 2023). This evidence concerns the gene CNTN2 and adult T-cell leukemia/lymphoma.